title: The role of lipid-based nano delivery systems on oral bioavailability enhancement of fenofibrate, a BCS II drug: comparison with fast-release formulations.
abstract: The aim of this study was to compare various formulations solid dispersion pellets (SDP), nanostructured lipid carriers (NLCs) and a self-microemulsifying drug delivery system (SMEDDS) generally accepted to be the most efficient drug delivery systems for BCS II drugs using fenofibrate (FNB) as a model drug. The size and morphology of NLCs and SMEDDS was characterized by dynamic light scattering (DLS) and transmission electron microscopy (TEM). Their release behaviors were investigated in medium with or without pancreatic lipase. The oral bioavailability of the various formulations was compared in beagle dogs using commercial Lipanthyl® capsules (micronized formulation) as a reference. The release of FNB from SDP was much faster than that from NLCs and SMEDDS in medium without lipase, whereas the release rate from NLCs and SMEDDS was increased after adding pancreatic lipase into the release medium. However, NLCs and SMEDDS increased the bioavailability of FNB to 705.11% and 809.10%, respectively, in comparison with Lipanthyl® capsules, although the relative bioavailability of FNB was only 366.05% after administration of SDPs. Thus, lipid-based drug delivery systems (such as NLCs and SMEDDS) may have more advantages than immediate release systems (such as SDPs and Lipanthyl® capsules).
authors.forename: Tengfei
authors.initials: T
authors.lastname: Weng
authors.forename: Jianping
authors.initials: J
authors.lastname: Qi
authors.forename: Yi
authors.initials: Y
authors.lastname: Lu
authors.forename: Kai
authors.initials: K
authors.lastname: Wang
authors.forename: Zhiqiang
authors.initials: Z
authors.lastname: Tian
authors.forename: Kaili
authors.initials: K
authors.lastname: Hu
authors.forename: Zongning
authors.initials: Z
authors.lastname: Yin
authors.forename: Wei
authors.initials: W
authors.lastname: Wu
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D002626:Chemistry, Pharmaceutical / Q000379:methods; D004285:Dogs; D004337:Drug Carriers / Q000008:administration & dosage; D016503:Drug Delivery Systems / Q000379:methods; D004655:Emulsions / Q000008:administration & dosage / Q000378:metabolism; D011345:Fenofibrate / Q000008:administration & dosage* / Q000378:metabolism*; D008055:Lipids / Q000008:administration & dosage*; D046529:Microscopy, Electron, Transmission / Q000379:methods; D049329:Nanostructures / Q000008:administration & dosage*; D010316:Particle Size
chemical_list: D004337:Drug Carriers; D004655:Emulsions; D008055:Lipids; D011345:Fenofibrate